苦参胶囊联合拉米夫定治疗慢性乙型肝炎的临床研究  

Study on matrine combined with Lamivued for chronic hepatitis B

作　　者：史志红[1] 高荣凯[1] 杨亚丽[1] 许明策[1] 

机构地区：[1]新乡市第一人民医院消化内科,河南省453000

出　　处：《实用诊断与治疗杂志》2005年第7期505-506,共2页Journal of Practical Diagnosis and Therapy

摘　　要：目的:观察苦参胶囊联合拉米夫定治疗慢性乙型肝炎的临床疗效。方法:34例HBeAg与HBVDNA均阳性的慢性乙肝患者接受苦参胶囊联合拉米夫定治疗12个月,并与30例单用拉米夫定治疗的患者进行对比。结果:疗程结束时,观察组HBVDNA阴转率为82.3%与对照组76.7%相比无明显差异(P>0.05)。观察组HBeAg阴转率为58.8%明显高于对照组36.7%(P<0.01)。疗程结束后随访6个月观察组HBeAg与HBVDNA持续阴转率为61.8%、85.4%明显高于对照组的33.3%、73.3%(P<0.01)。观察组HBeAg与HBVDNA的复发率明显低于对照组(P<0.05)。结论:苦参胶囊与拉米夫定联合应用有协同作用,可提高疗效,减少病毒耐药,降低复发率。Objective To observe the effect of matrine combined with Lamivued for chronic hep- atitis B. Methods Thirty-four chronic hepatitis B patients were treated with matrine combined with Lamivued for 12 months and another 30 chronic hepatitis B patients were treated with Lamivued at same time. Results HBVDNA negative rate was 82.3% in observed group and 76.7% in control group respectively.No significant difference was found between two groups(P>0.05).A significant eleva- tion was found in the expression of HBeAg loss in observe group (P<0.01).Six-month follow-up survery showed that the rate of sustained loss of both HBVDNA and HBeAg was significantly greater in observe group than that in control group (61.8% vs 33.3%,85.4% vs 73.3%,P<0.01).The re- currence rate of HBeAg and HBVDNA was significantly lower in observed group than that in control group (P<0.05). Conclusion The combined method can enhance the effect,reduce the number of virus of drug-resistant,and drop recurrence rate.

关 键 词：慢性乙型肝炎 苦参胶囊 拉米夫定 

分 类 号：R512.62[医药卫生—内科学]